Eur Rev Med Pharmacol Sci 2017; 21 (17): 3775-3780

Association between H19 polymorphisms and osteosarcoma risk

T.-D. He, D. Xu, T. Sui, J.-K. Zhu, Z.-X. Wei, Y.-M. Wang

Department of Orthopedics, The First People’s Hospital of Changzhou, Changzhou, Jiangsu Province, China. doctorwym51346@163.com


OBJECTIVE: The long non-coding RNA (lncRNA) H19, a maternally expressed imprinted gene, has involvement in cancer susceptibility and disease progression. However, the association between H19 polymorphisms and osteosarcoma susceptibility has remained elusive. We designed this case-control study to explore the association between H19 polymorphism and osteosarcoma risk.

PATIENTS AND METHODS: In this study, we genotyped 4 tagger SNPs of the H19 gene in a case-control study including 193 osteosarcoma cases and 393 cancer-free controls.

RESULTS: For the main effect analysis, rs217727 (G>A) was associated with osteosarcoma risk (GA/GG: adjusted OR = 1.51, 95% CI: 1.06-2.17, p = 0.024; AA/GG: adjusted OR = 1.89, 95% CI: 1.23-2.91, p = 0.004; additive model: adjusted OR = 1.35, 95% CI: 1.01-1.80, p = 0.043).

CONCLUSIONS: This finding indicates that rs217727 polymorphism may play a role in genetic susceptibility to the risk of osteosarcoma, which may improve our understanding of the potential contribution of H19 SNPs to cancer pathogenesis.

Free PDF Download

To cite this article

T.-D. He, D. Xu, T. Sui, J.-K. Zhu, Z.-X. Wei, Y.-M. Wang
Association between H19 polymorphisms and osteosarcoma risk

Eur Rev Med Pharmacol Sci
Year: 2017
Vol. 21 - N. 17
Pages: 3775-3780